The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis
Open accessAbstract
Purpose: Fluourouracil (FU) is a mainstay of chemotherapy, although toxicities are common. Genetic biomarkers have been used to predict these adverse events, but their utility is uncertain. Patients and Methods: We tested candidate polymorphisms identified from a systematic literature search for associations with capecitabine toxicity in 927 patients with colorectal cancer in the Quick and Simple and Reliable trial (QUASAR2). We then performed meta-analysis of QUASAR2 and 16 published studies (n = 4,855 patients) to examine the polymorphisms in various FU monotherapy and combination therapy regimens. Results: Global capecitabine toxicity (grades 0/1/2 v grades 3/4/5) was associated with the rare, functional DPYD alleles 2846T>A and *2A (combined odds ratio, 5.51; P = .0013) and with the common TYMS polymorphisms 5′VNTR2R/3R and 3′UTR 6bp ins-del (combined odds ratio, 1.31; P = 9.4 × 10−6). There was weaker evidence that these polymorphisms predict toxicity from bolus and infusional FU monotherapy. No good evidence of association with toxicity was found for the remaining polymorphisms, including several currently included in predictive kits. No polymorphisms were associated with toxicity in combination regimens. Conclusion: A panel of genetic biomarkers for capecitabine monotherapy toxicity would currently comprise only the four DPYD and TYMS variants above. We estimate this test could provide 26% sensitivity, 86% specificity, and 49% positive predictive value—better than most available commercial kits, but suboptimal for clinical use. The test panel might be extended to include additional, rare DPYD variants functionally equivalent to *2A and 2846A, though insufficient evidence supports its use in bolus, infusional, or combination FU. There remains a need to identify further markers of FU toxicity for all regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Self-citationDouillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., Carrato, A., Cassidy, J., Cervantes, A., Fagerberg, J., Georgoulias, V., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043116 · Cited by 1,248
Cassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., Debraud, F., Figer, A., Grossmann, J., Sawada, N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.069 · Cited by 525
5-Fluorouracil: Forty-Plus and Still Ticking. A Review of its Preclinical and Clinical Development
Grem, J. L. (2000) · Investigational New Drugs · doi:10.1023/a:1006416410198 · Cited by 417
Schwab, M., Zanger, U. M., Marx, C., Schaeffeler, E., Klein, K., Dippon, J., Kerb, R., Blievernicht, J., Fischer, J., Hofmann, U., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4182 · Cited by 393
Self-citationMandola, M. V., Stoehlmacher, J., Muller‐Weeks, S., Cesarone, G., Yu, M. C., Lenz, H., & Ladner, R. D. (2003) · PubMed · Cited by 362
Kuilenburg, A. B. P., Haasjes, J., Richel, D. J., Zoetekouw, L., van LENTHE, H., ABREU, R. A. D., Maring, J. G., Vreken, P., & Gennip, A. H. (2000) · PubMed · Cited by 359
Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency
Van Kuilenburg, A. B. P., Vreken, P., Abeling, N. G. G. M., Bakker, H. D., Meinsma, R., Van Lenthe, H., De Abreu, R. A., Smeitink, J. A. M., Kayserili, H., Apak, M. Y., et al. (1999) · Human Genetics · doi:10.1007/pl00008711 · Cited by 282
Lecomte, T., Ferraz, J.-M., Zinzindohoué, F., Loriot, M.-A., Tregouet, D.-A., Landi, B., Berger, A., Cugnenc, P.-H., Jian, R., Beaune, P., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0169 · Cited by 242
Self-citationMorel, A., Boisdron-Celle, M., Fey, L., Soulie, P., Craipeau, M. C., Traore, S., & Gamelin, E. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0327 · Cited by 236
Self-citationSaif, M. W., Choma, A., Salamone, S. J., & Chu, E. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp328 · Cited by 216
McLeod, H. L., Sargent, D. J., Marsh, S., Green, E. M., King, C. R., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Thibodeau, S. N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.7943 · Cited by 216
Self-citationDeenen, M. J., Tol, J., Burylo, A. M., Doodeman, V. D., de Boer, A., Vincent, A., Guchelaar, H.-J., Smits, P. H. M., Beijnen, J. H., Punt, C. J. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2209 · Cited by 191
Cohen, V., Panet-Raymond, V., Sabbaghian, N., Morin, I., Batist, G., & Rozen, R. R. (2003) · PubMed · Cited by 183
Boige, V., Mendiboure, J., Pignon, J.-P., Loriot, M.-A., Castaing, M., Barrois, M., Malka, D., Trégouët, D.-A., Bouché, O., Le Corre, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.2106 · Cited by 172
Self-citationBraun, M. S., Richman, S. D., Thompson, L. C., Daly, C. L., Meade, A. M., Adlard, J., Allan, J. M., Parmar, M., Quirke, P., & Seymour, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6283 · Cited by 128
Self-citationGlimelius, B. L. G., Garmo, H., Berglund, Å., Fredriksson, L. A., Berglund, M., Kohnke, H., Byström, P., Sørbye, H., & Wadelius, M. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.10 · Cited by 124
Self-citationOffer, S. M., Wegner, N. J., Fossum, C. C., Wang, K., & Diasio, R. B. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3858 · Cited by 121
Étienne-Grimaldi, M.-C., Milano, G. A., Maindrault‐Gœbel, F., Chibaudel, B., Formento, J., Francoual, M., Lledo, G., André, T., Mabro, M., Mineur, L., et al. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03556.x · Cited by 114
Self-citationSharma, R., Hoskins, J. M., Rivory, L. P., Zucknick, M., London, R., Liddle, C., & Clarke, S. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0425 · Cited by 107
Self-citationMolecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
Chua, W., Goldstein, D., Lee, C. K., Dhillon, H. M., Michael, M., Mitchell, P., Clarke, S. J., & Iacopetta, B. M. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605239 · Cited by 105
Groß, E., Busse, B., Riemenschneider, M. J., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0004003 · Cited by 103
Ruzzo, A., Graziano, F., Loupakis, F., Santini, D., Catalano, V., Bisonni, R., Ficarelli, R., Fontana, A., Andreoni, F., Falcone, A., et al. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500463 · Cited by 100
Gusella, M., Frigo, A. C., Bolzonella, C., Marinelli, R., Barile, C., Bononi, A., Crepaldi, G., Menon, D., Stievano, L., Toso, S., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605052 · Cited by 100
Self-citationMTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer
Afzal, S., Jensen, S. A., Vainer, B., Vogel, U. B., Matsen, J. P., Sørensen, J. B., Andersen, P. K., & Poulsen, H. E. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp046 · Cited by 85
Self-citationAfzal, S., Gusella, M., Vainer, B., Vogel, U. B., Andersen, J. T., Broedbaek, K., Petersen, M. A., Jimenez‐Solem, E., Bertolaso, L., Barile, C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0304 · Cited by 53
Self-citationZhang, Q., Zhao, Y.-P., Liao, Q., Hu, Y. J., Xu, Q., Zhou, L., & Shu, H. (2011) · PubMed · Cited by 8
Cited by
Amstutz, U., Henricks, L. M., Offer, S. M., Barbarino, J., Schellens, J. H. M., Swen, J. J., Klein, T. E., McLeod, H. L., Caudle, K. E., Diasio, R. B., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.911 · Cited by 694
Self-citationDong, S., Liang, S., Cheng, Z., Zhang, X., Luo, L., Li, L., Zhang, W., Li, S., Xu, Q., Zhong, M., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02229-6 · Cited by 458
Meulendijks, D., Henricks, L. M., Sonke, G. S., Deenen, M. J., Froehlich, T. K., Amstutz, U., Largiadèr, C. R., Jennings, B. A., Marinaki, A. M., Sanderson, J. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00286-7 · Cited by 381
Self-citationUpfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
Deenen, M. J., Meulendijks, D., Cats, A., Sechterberger, M. K., Severens, J. L., Boot, H., Smits, P. H., Rosing, H., Mandigers, C. M. P. W., Soesan, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.1325 · Cited by 360
Inorganic titanium dioxide nanoparticles induces cytotoxicity in colon cancer cells
Vigneshwaran, R., Ezhilarasan, D., & Rajeshkumar, S. (2021) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2021.108920 · Cited by 23
Metadata
- Authors
- Rosmarin, D., Palles, C., Church, D., Domingo, E., Jones, A., Johnstone, E., Wang, H., Love, S., Julier, P., Scudder, C., Nicholson, G., Gonzalez-Neira, A., Martin, M., Sargent, D., Green, E., McLeod, H., Zanger, U. M., Schwab, M., Braun, M., Seymour, M., Thompson, L., Lacas, B., Boige, V., Ribelles, N., Afzal, S., Enghusen, H., Jensen, S. A., Etienne-Grimaldi, M.-C., Milano, G., Wadelius, M., Glimelius, B., Garmo, H., Gusella, M., Lecomte, T., Laurent-Puig, P., Martinez-Balibrea, E., Sharma, R., Garcia-Foncillas, J., Kleibl, Z., Morel, A., Pignon, J.-P., Midgley, R., Kerr, D., & Tomlinson, I.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-04-01
- Volume
- 32
- Issue
- 10
- Pages
- 1031-1039
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2098584035
- Cited by
- 256
- References
- 29
- FWCI
- 9.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.